John Muir Medical Center - Wc
- Type
- Teaching hospital
- Where
- CONCORD, CA
- Medicare CCN
- 050180
- Received
- $205,388 in 171 records, 2020 ($385 general, $205,003 research)
- Source
- CMS Open Payments search ↗
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2020 | General payment | 2 | $385 |
| 2020 | Research payment | 169 | $205,003 |
By company
| Company | Records | Amount | Years |
|---|---|---|---|
| CSL Behring | 28 | $71,002 | 2020 |
| Clovis Oncology, Inc. | 9 | $47,317 | 2020 |
| BIOTRONIK INC. | 81 | $24,713 | 2020 |
| Roche Products Limited | 23 | $16,036 | 2020 |
| PFIZER INC. | 3 | $15,660 | 2020 |
| Celgene Corporation | 2 | $9,575 | 2020 |
| Genentech, Inc. | 7 | $9,286 | 2020 |
| E.R. Squibb & Sons, L.L.C. | 1 | $3,540 | 2020 |
| Boston Scientific Corporation | 4 | $3,300 | 2020 |
| Pharmacyclics LLC, an AbbVie Company | 10 | $2,572 | 2020 |
| Concordia Laboratories Inc. | 1 | $2,000 | 2020 |
| Linvatec Corporation | 1 | $359 | 2020 |
| Ethicon Inc. | 1 | $26 | 2020 |
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Research payment | 169 | $205,003 |
| Grant | 1 | $359 |
| Gift | 1 | $26 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2020-12-28 | Clovis Oncology, Inc. | $3,683 | Research payment | Cash or cash equivalent | Rubraca Drug, ONCOLOGY | A Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Fro | 2020 |
| 2020-12-28 | Clovis Oncology, Inc. | $317 | Research payment | Cash or cash equivalent | Rubraca Drug, ONCOLOGY | A Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Fro | 2020 |
| 2020-12-16 | Celgene Corporation | $662 | Research payment | Cash or cash equivalent | Revlimid Drug, Hematology | Celgene - Connect MDS/AML | 2020 |
| 2020-12-15 | CSL Behring | $10,234 | Research payment | Cash or cash equivalent | A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy a | 2020 | |
| 2020-12-15 | CSL Behring | $500 | Research payment | Cash or cash equivalent | A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy a | 2020 | |
| 2020-12-15 | CSL Behring | $400 | Research payment | Cash or cash equivalent | A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy a | 2020 | |
| 2020-12-15 | CSL Behring | $250 | Research payment | Cash or cash equivalent | A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy a | 2020 | |
| 2020-12-15 | Pharmacyclics LLC, an AbbVie Company | $202 | Research payment | Cash or cash equivalent | Imbruvica Drug, Oncology | PCYC-1134M-CA | 2020 |
| 2020-12-15 | Pharmacyclics LLC, an AbbVie Company | $202 | Research payment | Cash or cash equivalent | Imbruvica Drug, Oncology | PCYC-1134M-CA | 2020 |
| 2020-12-14 | Roche Products Limited | $200 | Research payment | Cash or cash equivalent | TECENTRIQ Biological, BioOncology | A PHASE III MULTICENTER RANDOMIZED OPEN LABEL STUDY COMPARING ATEZOLIZUMAB ANTI PD L1 ANTIBODY | 2020 |
| 2020-12-08 | Clovis Oncology, Inc. | $11,250 | Research payment | Cash or cash equivalent | Rubraca Drug, ONCOLOGY | A Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Fro | 2020 |
| 2020-12-08 | BIOTRONIK INC. | $437 | Research payment | Cash or cash equivalent | Orsiro Device, Cardiology/Vascular Diseases | BIOFLOW-VII | 2020 |
| 2020-12-08 | BIOTRONIK INC. | $437 | Research payment | Cash or cash equivalent | Orsiro Device, Cardiology/Vascular Diseases | BIOFLOW-VII | 2020 |
| 2020-12-08 | BIOTRONIK INC. | $437 | Research payment | Cash or cash equivalent | Orsiro Device, Cardiology/Vascular Diseases | BIOFLOW-VII | 2020 |
| 2020-12-08 | BIOTRONIK INC. | $437 | Research payment | Cash or cash equivalent | Orsiro Device, Cardiology/Vascular Diseases | BIOFLOW-VII | 2020 |
| 2020-12-08 | BIOTRONIK INC. | $437 | Research payment | Cash or cash equivalent | Orsiro Device, Cardiology/Vascular Diseases | BIOFLOW-VII | 2020 |
| 2020-12-08 | BIOTRONIK INC. | $357 | Research payment | Cash or cash equivalent | Orsiro Device, Cardiology/Vascular Diseases | BIOFLOW-VII | 2020 |
| 2020-12-08 | BIOTRONIK INC. | $357 | Research payment | Cash or cash equivalent | Orsiro Device, Cardiology/Vascular Diseases | BIOFLOW-VII | 2020 |
| 2020-12-08 | BIOTRONIK INC. | $357 | Research payment | Cash or cash equivalent | Orsiro Device, Cardiology/Vascular Diseases | BIOFLOW-VII | 2020 |
| 2020-12-08 | BIOTRONIK INC. | $357 | Research payment | Cash or cash equivalent | Orsiro Device, Cardiology/Vascular Diseases | BIOFLOW-VII | 2020 |
| 2020-12-08 | BIOTRONIK INC. | $357 | Research payment | Cash or cash equivalent | Orsiro Device, Cardiology/Vascular Diseases | BIOFLOW-VII | 2020 |
| 2020-12-08 | BIOTRONIK INC. | $357 | Research payment | Cash or cash equivalent | Orsiro Device, Cardiology/Vascular Diseases | BIOFLOW-VII | 2020 |
| 2020-12-08 | BIOTRONIK INC. | $357 | Research payment | Cash or cash equivalent | Orsiro Device, Cardiology/Vascular Diseases | BIOFLOW-VII | 2020 |
| 2020-12-08 | BIOTRONIK INC. | $357 | Research payment | Cash or cash equivalent | Orsiro Device, Cardiology/Vascular Diseases | BIOFLOW-VII | 2020 |
| 2020-12-08 | BIOTRONIK INC. | $357 | Research payment | Cash or cash equivalent | Orsiro Device, Cardiology/Vascular Diseases | BIOFLOW-VII | 2020 |
| 2020-12-08 | BIOTRONIK INC. | $357 | Research payment | Cash or cash equivalent | Orsiro Device, Cardiology/Vascular Diseases | BIOFLOW-VII | 2020 |
| 2020-12-08 | BIOTRONIK INC. | $357 | Research payment | Cash or cash equivalent | Orsiro Device, Cardiology/Vascular Diseases | BIOFLOW-VII | 2020 |
| 2020-12-08 | BIOTRONIK INC. | $350 | Research payment | Cash or cash equivalent | Orsiro Device, Cardiology/Vascular Diseases | BIOFLOW-VII | 2020 |
| 2020-12-08 | BIOTRONIK INC. | $139 | Research payment | Cash or cash equivalent | Orsiro Device, Cardiology/Vascular Diseases | BIOFLOW-VII | 2020 |
| 2020-12-08 | BIOTRONIK INC. | $139 | Research payment | Cash or cash equivalent | Orsiro Device, Cardiology/Vascular Diseases | BIOFLOW-VII | 2020 |
| 2020-12-08 | BIOTRONIK INC. | $139 | Research payment | Cash or cash equivalent | Orsiro Device, Cardiology/Vascular Diseases | BIOFLOW-VII | 2020 |
| 2020-12-08 | BIOTRONIK INC. | $139 | Research payment | Cash or cash equivalent | Orsiro Device, Cardiology/Vascular Diseases | BIOFLOW-VII | 2020 |
| 2020-12-08 | BIOTRONIK INC. | $139 | Research payment | Cash or cash equivalent | Orsiro Device, Cardiology/Vascular Diseases | BIOFLOW-VII | 2020 |
| 2020-12-08 | BIOTRONIK INC. | $139 | Research payment | Cash or cash equivalent | Orsiro Device, Cardiology/Vascular Diseases | BIOFLOW-VII | 2020 |
| 2020-12-08 | BIOTRONIK INC. | $79 | Research payment | Cash or cash equivalent | Orsiro Device, Cardiology/Vascular Diseases | BIOFLOW-VII | 2020 |
| 2020-12-08 | BIOTRONIK INC. | $79 | Research payment | Cash or cash equivalent | Orsiro Device, Cardiology/Vascular Diseases | BIOFLOW-VII | 2020 |
| 2020-12-08 | BIOTRONIK INC. | $79 | Research payment | Cash or cash equivalent | Orsiro Device, Cardiology/Vascular Diseases | BIOFLOW-VII | 2020 |
| 2020-12-08 | BIOTRONIK INC. | $79 | Research payment | Cash or cash equivalent | Orsiro Device, Cardiology/Vascular Diseases | BIOFLOW-VII | 2020 |
| 2020-12-08 | BIOTRONIK INC. | $79 | Research payment | Cash or cash equivalent | Orsiro Device, Cardiology/Vascular Diseases | BIOFLOW-VII | 2020 |
| 2020-12-08 | BIOTRONIK INC. | $79 | Research payment | Cash or cash equivalent | Orsiro Device, Cardiology/Vascular Diseases | BIOFLOW-VII | 2020 |
| 2020-12-08 | BIOTRONIK INC. | $53 | Research payment | Cash or cash equivalent | Orsiro Device, Cardiology/Vascular Diseases | BIOFLOW-VII | 2020 |
| 2020-12-08 | BIOTRONIK INC. | $53 | Research payment | Cash or cash equivalent | Orsiro Device, Cardiology/Vascular Diseases | BIOFLOW-VII | 2020 |
| 2020-12-08 | BIOTRONIK INC. | $53 | Research payment | Cash or cash equivalent | Orsiro Device, Cardiology/Vascular Diseases | BIOFLOW-VII | 2020 |
| 2020-12-08 | BIOTRONIK INC. | $53 | Research payment | Cash or cash equivalent | Orsiro Device, Cardiology/Vascular Diseases | BIOFLOW-VII | 2020 |
| 2020-12-08 | BIOTRONIK INC. | $53 | Research payment | Cash or cash equivalent | Orsiro Device, Cardiology/Vascular Diseases | BIOFLOW-VII | 2020 |
| 2020-12-08 | BIOTRONIK INC. | $53 | Research payment | Cash or cash equivalent | Orsiro Device, Cardiology/Vascular Diseases | BIOFLOW-VII | 2020 |
| 2020-12-08 | BIOTRONIK INC. | $53 | Research payment | Cash or cash equivalent | Orsiro Device, Cardiology/Vascular Diseases | BIOFLOW-VII | 2020 |
| 2020-12-08 | BIOTRONIK INC. | $53 | Research payment | Cash or cash equivalent | Orsiro Device, Cardiology/Vascular Diseases | BIOFLOW-VII | 2020 |
| 2020-12-08 | BIOTRONIK INC. | $53 | Research payment | Cash or cash equivalent | Orsiro Device, Cardiology/Vascular Diseases | BIOFLOW-VII | 2020 |
| 2020-12-08 | BIOTRONIK INC. | $53 | Research payment | Cash or cash equivalent | Orsiro Device, Cardiology/Vascular Diseases | BIOFLOW-VII | 2020 |
| 2020-12-08 | BIOTRONIK INC. | $53 | Research payment | Cash or cash equivalent | Orsiro Device, Cardiology/Vascular Diseases | BIOFLOW-VII | 2020 |
| 2020-12-08 | BIOTRONIK INC. | $53 | Research payment | Cash or cash equivalent | Orsiro Device, Cardiology/Vascular Diseases | BIOFLOW-VII | 2020 |
| 2020-12-08 | BIOTRONIK INC. | $53 | Research payment | Cash or cash equivalent | Orsiro Device, Cardiology/Vascular Diseases | BIOFLOW-VII | 2020 |
| 2020-12-08 | BIOTRONIK INC. | $53 | Research payment | Cash or cash equivalent | Orsiro Device, Cardiology/Vascular Diseases | BIOFLOW-VII | 2020 |
| 2020-12-08 | BIOTRONIK INC. | $26 | Research payment | Cash or cash equivalent | Orsiro Device, Cardiology/Vascular Diseases | BIOFLOW-VII | 2020 |
| 2020-12-08 | BIOTRONIK INC. | $26 | Research payment | Cash or cash equivalent | Orsiro Device, Cardiology/Vascular Diseases | BIOFLOW-VII | 2020 |
| 2020-12-08 | BIOTRONIK INC. | $26 | Research payment | Cash or cash equivalent | Orsiro Device, Cardiology/Vascular Diseases | BIOFLOW-VII | 2020 |
| 2020-12-08 | BIOTRONIK INC. | $26 | Research payment | Cash or cash equivalent | Orsiro Device, Cardiology/Vascular Diseases | BIOFLOW-VII | 2020 |
| 2020-12-08 | BIOTRONIK INC. | $26 | Research payment | Cash or cash equivalent | Orsiro Device, Cardiology/Vascular Diseases | BIOFLOW-VII | 2020 |
| 2020-12-08 | BIOTRONIK INC. | $26 | Research payment | Cash or cash equivalent | Orsiro Device, Cardiology/Vascular Diseases | BIOFLOW-VII | 2020 |
| 2020-12-08 | BIOTRONIK INC. | $26 | Research payment | Cash or cash equivalent | Orsiro Device, Cardiology/Vascular Diseases | BIOFLOW-VII | 2020 |
| 2020-12-07 | Roche Products Limited | $750 | Research payment | Cash or cash equivalent | TECENTRIQ Biological, BioOncology | A PHASE III MULTICENTER RANDOMIZED OPEN LABEL STUDY COMPARING ATEZOLIZUMAB ANTI PD L1 ANTIBODY | 2020 |
| 2020-12-07 | Roche Products Limited | $750 | Research payment | Cash or cash equivalent | TECENTRIQ Biological, BioOncology | A PHASE III MULTICENTER RANDOMIZED OPEN LABEL STUDY COMPARING ATEZOLIZUMAB ANTI PD L1 ANTIBODY | 2020 |
| 2020-12-07 | Roche Products Limited | $200 | Research payment | Cash or cash equivalent | TECENTRIQ Biological, BioOncology | A PHASE III MULTICENTER RANDOMIZED OPEN LABEL STUDY COMPARING ATEZOLIZUMAB ANTI PD L1 ANTIBODY | 2020 |
| 2020-12-07 | Roche Products Limited | $200 | Research payment | Cash or cash equivalent | TECENTRIQ Biological, BioOncology | A PHASE III MULTICENTER RANDOMIZED OPEN LABEL STUDY COMPARING ATEZOLIZUMAB ANTI PD L1 ANTIBODY | 2020 |
| 2020-12-07 | Roche Products Limited | $200 | Research payment | Cash or cash equivalent | TECENTRIQ Biological, BioOncology | A PHASE III MULTICENTER RANDOMIZED OPEN LABEL STUDY COMPARING ATEZOLIZUMAB ANTI PD L1 ANTIBODY | 2020 |
| 2020-12-07 | Roche Products Limited | $200 | Research payment | Cash or cash equivalent | TECENTRIQ Biological, BioOncology | A PHASE III MULTICENTER RANDOMIZED OPEN LABEL STUDY COMPARING ATEZOLIZUMAB ANTI PD L1 ANTIBODY | 2020 |
| 2020-12-07 | Roche Products Limited | $200 | Research payment | Cash or cash equivalent | TECENTRIQ Biological, BioOncology | A PHASE III MULTICENTER RANDOMIZED OPEN LABEL STUDY COMPARING ATEZOLIZUMAB ANTI PD L1 ANTIBODY | 2020 |
| 2020-12-07 | Roche Products Limited | $200 | Research payment | Cash or cash equivalent | TECENTRIQ Biological, BioOncology | A PHASE III MULTICENTER RANDOMIZED OPEN LABEL STUDY COMPARING ATEZOLIZUMAB ANTI PD L1 ANTIBODY | 2020 |
| 2020-12-07 | Roche Products Limited | $200 | Research payment | Cash or cash equivalent | TECENTRIQ Biological, BioOncology | A PHASE III MULTICENTER RANDOMIZED OPEN LABEL STUDY COMPARING ATEZOLIZUMAB ANTI PD L1 ANTIBODY | 2020 |
| 2020-11-17 | CSL Behring | $1,250 | Research payment | Cash or cash equivalent | A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy a | 2020 | |
| 2020-11-16 | Roche Products Limited | $400 | Research payment | Cash or cash equivalent | TECENTRIQ Biological, BioOncology | A PHASE III MULTICENTER RANDOMIZED OPEN LABEL STUDY COMPARING ATEZOLIZUMAB ANTI PD L1 ANTIBODY | 2020 |
| 2020-11-03 | BIOTRONIK INC. | $300 | Research payment | Cash or cash equivalent | Orsiro Device, Cardiology/Vascular Diseases | BIOFLOW-VII | 2020 |
| 2020-11-02 | Roche Products Limited | $200 | Research payment | Cash or cash equivalent | TECENTRIQ Biological, BioOncology | A PHASE III MULTICENTER RANDOMIZED OPEN LABEL STUDY COMPARING ATEZOLIZUMAB ANTI PD L1 ANTIBODY | 2020 |
| 2020-10-29 | Clovis Oncology, Inc. | $3,046 | Research payment | Cash or cash equivalent | Rubraca Drug, ONCOLOGY | A Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Fro | 2020 |
| 2020-10-14 | BIOTRONIK INC. | $277 | Research payment | Cash or cash equivalent | Orsiro Device, Cardiology/Vascular Diseases | BIOFLOW-V | 2020 |
| 2020-10-14 | BIOTRONIK INC. | $277 | Research payment | Cash or cash equivalent | Orsiro Device, Cardiology/Vascular Diseases | BIOFLOW-V | 2020 |
| 2020-10-06 | CSL Behring | $534 | Research payment | Cash or cash equivalent | A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy a | 2020 | |
| 2020-09-17 | Pharmacyclics LLC, an AbbVie Company | $202 | Research payment | Cash or cash equivalent | Imbruvica Drug, Oncology | PCYC-1134M-CA | 2020 |
| 2020-09-10 | CSL Behring | $267 | Research payment | Cash or cash equivalent | A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy a | 2020 | |
| 2020-09-09 | BIOTRONIK INC. | $324 | Research payment | Cash or cash equivalent | Orsiro Device, Cardiology/Vascular Diseases | BIOFLOW-V | 2020 |
| 2020-09-09 | BIOTRONIK INC. | $324 | Research payment | Cash or cash equivalent | Orsiro Device, Cardiology/Vascular Diseases | BIOFLOW-V | 2020 |
| 2020-09-09 | BIOTRONIK INC. | $277 | Research payment | Cash or cash equivalent | Orsiro Device, Cardiology/Vascular Diseases | BIOFLOW-V | 2020 |
| 2020-09-01 | BIOTRONIK INC. | $6,500 | Research payment | Cash or cash equivalent | Orsiro Device, Cardiology/Vascular Diseases | BIOFLOW-VII | 2020 |
| 2020-08-11 | CSL Behring | $764 | Research payment | Cash or cash equivalent | A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy a | 2020 | |
| 2020-08-11 | BIOTRONIK INC. | $440 | Research payment | Cash or cash equivalent | Orsiro Device, Cardiology/Vascular Diseases | BIOFLOW-V | 2020 |
| 2020-08-11 | BIOTRONIK INC. | $324 | Research payment | Cash or cash equivalent | Orsiro Device, Cardiology/Vascular Diseases | BIOFLOW-V | 2020 |
| 2020-08-11 | BIOTRONIK INC. | $324 | Research payment | Cash or cash equivalent | Orsiro Device, Cardiology/Vascular Diseases | BIOFLOW-V | 2020 |
| 2020-08-11 | BIOTRONIK INC. | $324 | Research payment | Cash or cash equivalent | Orsiro Device, Cardiology/Vascular Diseases | BIOFLOW-V | 2020 |
| 2020-08-11 | BIOTRONIK INC. | $277 | Research payment | Cash or cash equivalent | Orsiro Device, Cardiology/Vascular Diseases | BIOFLOW-V | 2020 |
| 2020-08-11 | BIOTRONIK INC. | $277 | Research payment | Cash or cash equivalent | Orsiro Device, Cardiology/Vascular Diseases | BIOFLOW-V | 2020 |
| 2020-08-11 | BIOTRONIK INC. | $277 | Research payment | Cash or cash equivalent | Orsiro Device, Cardiology/Vascular Diseases | BIOFLOW-V | 2020 |
| 2020-08-11 | BIOTRONIK INC. | $277 | Research payment | Cash or cash equivalent | Orsiro Device, Cardiology/Vascular Diseases | BIOFLOW-V | 2020 |
| 2020-08-11 | BIOTRONIK INC. | $277 | Research payment | Cash or cash equivalent | Orsiro Device, Cardiology/Vascular Diseases | BIOFLOW-V | 2020 |
| 2020-08-11 | BIOTRONIK INC. | $170 | Research payment | Cash or cash equivalent | Orsiro Device, Cardiology/Vascular Diseases | BIOFLOW-V | 2020 |
| 2020-08-10 | Clovis Oncology, Inc. | $4,122 | Research payment | Cash or cash equivalent | Rubraca Drug, ONCOLOGY | A Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Fro | 2020 |
| 2020-08-03 | Roche Products Limited | $1,803 | Research payment | Cash or cash equivalent | TECENTRIQ Biological, BioOncology | A PHASE III MULTICENTER RANDOMIZED OPEN LABEL STUDY COMPARING ATEZOLIZUMAB ANTI PD L1 ANTIBODY | 2020 |
| 2020-07-27 | Roche Products Limited | $750 | Research payment | Cash or cash equivalent | TECENTRIQ Biological, BioOncology | A PHASE III MULTICENTER RANDOMIZED OPEN LABEL STUDY COMPARING ATEZOLIZUMAB ANTI PD L1 ANTIBODY | 2020 |
| 2020-07-27 | Roche Products Limited | $200 | Research payment | Cash or cash equivalent | TECENTRIQ Biological, BioOncology | A PHASE III MULTICENTER RANDOMIZED OPEN LABEL STUDY COMPARING ATEZOLIZUMAB ANTI PD L1 ANTIBODY | 2020 |
| 2020-07-23 | Genentech, Inc. | $500 | Research payment | Cash or cash equivalent | Non-Covered Product Drug, None | TENECTEPLASE IN STROKE PATIENTS BETWEEN 4 5 AND 24 HOURS | 2020 |
| 2020-07-23 | Genentech, Inc. | $459 | Research payment | Cash or cash equivalent | Non-Covered Product Drug, None | TENECTEPLASE IN STROKE PATIENTS BETWEEN 4 5 AND 24 HOURS | 2020 |
| 2020-07-20 | Roche Products Limited | $895 | Research payment | Cash or cash equivalent | TECENTRIQ Biological, BioOncology | A PHASE III MULTICENTER RANDOMIZED OPEN LABEL STUDY COMPARING ATEZOLIZUMAB ANTI PD L1 ANTIBODY | 2020 |
| 2020-07-16 | Pharmacyclics LLC, an AbbVie Company | $202 | Research payment | Cash or cash equivalent | Imbruvica Drug, Oncology | PCYC-1134M-CA | 2020 |
| 2020-07-09 | CSL Behring | $4,314 | Research payment | Cash or cash equivalent | A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy a | 2020 | |
| 2020-07-07 | CSL Behring | $1,250 | Research payment | Cash or cash equivalent | A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy a | 2020 | |
| 2020-07-02 | Genentech, Inc. | $459 | Research payment | Cash or cash equivalent | Non-Covered Product Drug, None | TENECTEPLASE IN STROKE PATIENTS BETWEEN 4 5 AND 24 HOURS | 2020 |
| 2020-07-01 | PFIZER INC. | $11,350 | Research payment | Cash or cash equivalent | IBRANCE Drug, ONCOLOGY | POLARIS PALBOCICLIB IN HORMONE RECEPTOR POSITIVE ADVANCED BREAST CANCER A PROSPECTIVE MULTICENTER NONINTERVENTIONAL STUD | 2020 |
| 2020-06-30 | Genentech, Inc. | $1,822 | Research payment | Cash or cash equivalent | Non-Covered Product Drug, None | TENECTEPLASE IN STROKE PATIENTS BETWEEN 4 5 AND 24 HOURS | 2020 |
| 2020-06-25 | Genentech, Inc. | $3,942 | Research payment | Cash or cash equivalent | Non-Covered Product Drug, None | TENECTEPLASE IN STROKE PATIENTS BETWEEN 4 5 AND 24 HOURS | 2020 |
| 2020-06-22 | Roche Products Limited | $200 | Research payment | Cash or cash equivalent | TECENTRIQ Biological, BioOncology | A PHASE III MULTICENTER RANDOMIZED OPEN LABEL STUDY COMPARING ATEZOLIZUMAB ANTI PD L1 ANTIBODY | 2020 |
| 2020-06-11 | Pharmacyclics LLC, an AbbVie Company | $202 | Research payment | Cash or cash equivalent | Imbruvica Drug, Oncology | PCYC-1134M-CA | 2020 |
| 2020-06-11 | Pharmacyclics LLC, an AbbVie Company | $202 | Research payment | Cash or cash equivalent | Imbruvica Drug, Oncology | PCYC-1134M-CA | 2020 |
| 2020-06-11 | Pharmacyclics LLC, an AbbVie Company | $202 | Research payment | Cash or cash equivalent | Imbruvica Drug, Oncology | PCYC-1134M-CA | 2020 |
| 2020-06-11 | Pharmacyclics LLC, an AbbVie Company | $202 | Research payment | Cash or cash equivalent | Imbruvica Drug, Oncology | PCYC-1134M-CA | 2020 |
| 2020-06-09 | Genentech, Inc. | $1,604 | Research payment | Cash or cash equivalent | Non-Covered Product Drug, None | TENECTEPLASE IN STROKE PATIENTS BETWEEN 4 5 AND 24 HOURS | 2020 |
| 2020-06-08 | Clovis Oncology, Inc. | $6,811 | Research payment | Cash or cash equivalent | Rubraca Drug, ONCOLOGY | A Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Fro | 2020 |
| 2020-06-08 | Roche Products Limited | $750 | Research payment | Cash or cash equivalent | TECENTRIQ Biological, BioOncology | A PHASE III MULTICENTER RANDOMIZED OPEN LABEL STUDY COMPARING ATEZOLIZUMAB ANTI PD L1 ANTIBODY | 2020 |
| 2020-06-04 | CSL Behring | $764 | Research payment | Cash or cash equivalent | A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy a | 2020 | |
| 2020-05-27 | Concordia Laboratories Inc. | $2,000 | Research payment | Cash or cash equivalent | Photofrin Drug, Oncology | PDT Registry | 2020 |
| 2020-05-27 | BIOTRONIK INC. | $750 | Research payment | Cash or cash equivalent | Orsiro Device, Cardiology/Vascular Diseases | BIOFLOW-V | 2020 |
| 2020-05-27 | BIOTRONIK INC. | $250 | Research payment | Cash or cash equivalent | Orsiro Device, Cardiology/Vascular Diseases | BIOFLOW-V | 2020 |
| 2020-05-26 | CSL Behring | $750 | Research payment | Cash or cash equivalent | A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy a | 2020 | |
| 2020-05-26 | CSL Behring | $750 | Research payment | Cash or cash equivalent | A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy a | 2020 | |
| 2020-05-26 | CSL Behring | $500 | Research payment | Cash or cash equivalent | A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy a | 2020 | |
| 2020-05-26 | CSL Behring | $500 | Research payment | Cash or cash equivalent | A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy a | 2020 | |
| 2020-05-15 | PFIZER INC. | $1,500 | Research payment | Cash or cash equivalent | IBRANCE Drug, ONCOLOGY | POLARIS PALBOCICLIB IN HORMONE RECEPTOR POSITIVE ADVANCED BREAST CANCER A PROSPECTIVE MULTICENTER NONINTERVENTIONAL STUD | 2020 |
| 2020-05-14 | PFIZER INC. | $2,810 | Research payment | Cash or cash equivalent | IBRANCE Drug, ONCOLOGY | POLARIS PALBOCICLIB IN HORMONE RECEPTOR POSITIVE ADVANCED BREAST CANCER A PROSPECTIVE MULTICENTER NONINTERVENTIONAL STUD | 2020 |
| 2020-05-14 | CSL Behring | $285 | Research payment | Cash or cash equivalent | A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy a | 2020 | |
| 2020-05-14 | Clovis Oncology, Inc. | $158 | Research payment | Cash or cash equivalent | Rubraca Drug, ONCOLOGY | A Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Fro | 2020 |
| 2020-04-30 | Clovis Oncology, Inc. | $750 | Research payment | Cash or cash equivalent | Rubraca Drug, ONCOLOGY | A Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Fro | 2020 |
| 2020-04-27 | Roche Products Limited | $895 | Research payment | Cash or cash equivalent | TECENTRIQ Biological, BioOncology | A PHASE III MULTICENTER RANDOMIZED OPEN LABEL STUDY COMPARING ATEZOLIZUMAB ANTI PD L1 ANTIBODY | 2020 |
| 2020-04-14 | BIOTRONIK INC. | $324 | Research payment | Cash or cash equivalent | Orsiro Device, Cardiology/Vascular Diseases | BIOFLOW-V | 2020 |
| 2020-04-14 | BIOTRONIK INC. | $324 | Research payment | Cash or cash equivalent | Orsiro Device, Cardiology/Vascular Diseases | BIOFLOW-V | 2020 |
| 2020-04-14 | BIOTRONIK INC. | $277 | Research payment | Cash or cash equivalent | Orsiro Device, Cardiology/Vascular Diseases | BIOFLOW-V | 2020 |
| 2020-04-14 | BIOTRONIK INC. | $277 | Research payment | Cash or cash equivalent | Orsiro Device, Cardiology/Vascular Diseases | BIOFLOW-V | 2020 |
| 2020-04-14 | CSL Behring | $150 | Research payment | Cash or cash equivalent | A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy a | 2020 | |
| 2020-04-09 | CSL Behring | $3,916 | Research payment | Cash or cash equivalent | A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy a | 2020 | |
| 2020-04-09 | Ethicon Inc. | $26 | Gift | In-kind items and services | 2020 | ||
| 2020-04-06 | Boston Scientific Corporation | $1,300 | Research payment | Cash or cash equivalent | SYNERGY Device, STENTS | EVOLVE SHORT DAPT | 2020 |
| 2020-04-06 | Boston Scientific Corporation | $1,000 | Research payment | Cash or cash equivalent | SYNERGY Device, STENTS | EVOLVE SHORT DAPT | 2020 |
| 2020-04-06 | Boston Scientific Corporation | $750 | Research payment | Cash or cash equivalent | SYNERGY Device, STENTS | EVOLVE SHORT DAPT | 2020 |
| 2020-04-06 | Roche Products Limited | $200 | Research payment | Cash or cash equivalent | TECENTRIQ Biological, BioOncology | A PHASE III MULTICENTER RANDOMIZED OPEN LABEL STUDY COMPARING ATEZOLIZUMAB ANTI PD L1 ANTIBODY | 2020 |
| 2020-03-19 | Genentech, Inc. | $500 | Research payment | Cash or cash equivalent | Non-Covered Product Drug, None | TENECTEPLASE IN STROKE PATIENTS BETWEEN 4 5 AND 24 HOURS | 2020 |
| 2020-03-12 | CSL Behring | $9,187 | Research payment | Cash or cash equivalent | A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy a | 2020 | |
| 2020-03-12 | CSL Behring | $500 | Research payment | Cash or cash equivalent | A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy a | 2020 | |
| 2020-03-10 | E.R. Squibb & Sons, L.L.C. | $3,540 | Research payment | Cash or cash equivalent | OPDIVO Biological, Oncology | A Phase IIIb/IV Safety Trial of Nivolumab (BMS-936558) in Subjects with Advanced or Metastatic Non-Small Cell Lung Cance | 2020 |
| 2020-03-10 | CSL Behring | $750 | Research payment | Cash or cash equivalent | A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy a | 2020 | |
| 2020-03-10 | CSL Behring | $750 | Research payment | Cash or cash equivalent | A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy a | 2020 | |
| 2020-03-10 | BIOTRONIK INC. | $324 | Research payment | Cash or cash equivalent | Orsiro Device, Cardiology/Vascular Diseases | BIOFLOW-V | 2020 |
| 2020-03-10 | BIOTRONIK INC. | $324 | Research payment | Cash or cash equivalent | Orsiro Device, Cardiology/Vascular Diseases | BIOFLOW-V | 2020 |
| 2020-03-10 | BIOTRONIK INC. | $324 | Research payment | Cash or cash equivalent | Orsiro Device, Cardiology/Vascular Diseases | BIOFLOW-V | 2020 |
| 2020-03-10 | BIOTRONIK INC. | $324 | Research payment | Cash or cash equivalent | Orsiro Device, Cardiology/Vascular Diseases | BIOFLOW-V | 2020 |
| 2020-03-10 | BIOTRONIK INC. | $324 | Research payment | Cash or cash equivalent | Orsiro Device, Cardiology/Vascular Diseases | BIOFLOW-V | 2020 |
| 2020-03-10 | BIOTRONIK INC. | $324 | Research payment | Cash or cash equivalent | Orsiro Device, Cardiology/Vascular Diseases | BIOFLOW-V | 2020 |
| 2020-03-10 | BIOTRONIK INC. | $324 | Research payment | Cash or cash equivalent | Orsiro Device, Cardiology/Vascular Diseases | BIOFLOW-V | 2020 |
| 2020-03-10 | BIOTRONIK INC. | $277 | Research payment | Cash or cash equivalent | Orsiro Device, Cardiology/Vascular Diseases | BIOFLOW-V | 2020 |
| 2020-03-02 | Boston Scientific Corporation | $250 | Research payment | Cash or cash equivalent | SYNERGY Device, STENTS | EVOLVE SHORT DAPT | 2020 |
| 2020-02-24 | Roche Products Limited | $200 | Research payment | Cash or cash equivalent | TECENTRIQ Biological, BioOncology | A PHASE III MULTICENTER RANDOMIZED OPEN LABEL STUDY COMPARING ATEZOLIZUMAB ANTI PD L1 ANTIBODY | 2020 |
| 2020-02-24 | Roche Products Limited | $200 | Research payment | Cash or cash equivalent | TECENTRIQ Biological, BioOncology | A PHASE III MULTICENTER RANDOMIZED OPEN LABEL STUDY COMPARING ATEZOLIZUMAB ANTI PD L1 ANTIBODY | 2020 |
| 2020-02-17 | Celgene Corporation | $8,912 | Research payment | Cash or cash equivalent | Revlimid Drug, Hematology | Celgene - Connect MDS/AML | 2020 |
| 2020-02-13 | CSL Behring | $17,511 | Research payment | Cash or cash equivalent | A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy a | 2020 | |
| 2020-02-13 | CSL Behring | $600 | Research payment | Cash or cash equivalent | A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy a | 2020 | |
| 2020-02-11 | Clovis Oncology, Inc. | $17,177 | Research payment | Cash or cash equivalent | Rubraca Drug, ONCOLOGY | A Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Fro | 2020 |
| 2020-02-10 | Pharmacyclics LLC, an AbbVie Company | $202 | Research payment | Cash or cash equivalent | Imbruvica Drug, Oncology | PCYC-1134M-CA | 2020 |
| 2020-02-07 | Linvatec Corporation | $359 | Grant | In-kind items and services | SHOULDER MANUAL INSTRUMENTS Device, ORTHOPEDIC SURGERY | 2020 | |
| 2020-01-27 | Roche Products Limited | $6,241 | Research payment | Cash or cash equivalent | TECENTRIQ Biological, BioOncology | A PHASE III MULTICENTER RANDOMIZED OPEN LABEL STUDY COMPARING ATEZOLIZUMAB ANTI PD L1 ANTIBODY | 2020 |
| 2020-01-09 | CSL Behring | $13,172 | Research payment | Cash or cash equivalent | A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy a | 2020 | |
| 2020-01-09 | CSL Behring | $400 | Research payment | Cash or cash equivalent | A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy a | 2020 | |
| 2020-01-07 | CSL Behring | $375 | Research payment | Cash or cash equivalent | A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy a | 2020 | |
| 2020-01-07 | CSL Behring | $375 | Research payment | Cash or cash equivalent | A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy a | 2020 | |
| 2020-01-02 | Pharmacyclics LLC, an AbbVie Company | $750 | Research payment | Cash or cash equivalent | Imbruvica Drug, Oncology | PCYC-1134M-CA | 2020 |
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In Concord, CA, county Contra Costa County, CA, state California; placed by its city name.
| Measure | Place (city or town) Concord, CA | County Contra Costa County, CA | State California |
|---|---|---|---|
| Population B01003 | 124,035 | 1,165,012 | 39,287,377 |
| Population, 2020 census P1 | 125,410 | 1,165,927 | 39,538,223 |
| Median age B01002 | 39.1 | 40.5 | 37.9 |
| Under 18 B01001 | 21.3% | 22.0% | 22.0% |
| 65 and over B01001 | 16.4% | 17.1% | 15.7% |
| Households B11001 | 46,236 | 414,417 | 13,548,091 |
| Foreign born B05002 | 25.5% | 26.6% | 27.0% |
| Median household income B19013 | $108,709 | $127,229 | $99,122 |
| Median family income B19113 | $127,414 | $148,679 | $113,346 |
| Per capita income B19301 | $51,973 | $62,927 | $49,513 |
| Poverty rate B17001 | 8.2% | 8.4% | 12.0% |
| Unemployment rate B23025 | 5.4% | 6.5% | 6.6% |
| Civilian labor force B23025 | 66,669 | 608,620 | 20,068,466 |
| Mean commute (minutes) B08013 | 32.6 | 35.3 | 28.7 |
| Bachelor's degree or higher B15003 | 37.5% | 45.2% | 37.1% |
| Housing units B25001 | 47,703 | 429,260 | 14,644,735 |
| Owner-occupied B25003 | 61.6% | 68.0% | 55.9% |
| Renters B25003 | 38.4% | 32.0% | 44.1% |
| Median home value B25077 | $797,600 | $866,800 | $734,700 |
| Median gross rent B25064 | $2,274 | $2,375 | $2,036 |
| White, not Hispanic B03002 | 41.6% | 38.1% | 33.8% |
| Black B03002 | 3.7% | 7.9% | 5.2% |
| Hispanic or Latino B03002 | 32.4% | 27.6% | 40.2% |
| Asian B03002 | 13.7% | 18.6% | 15.3% |
| American Indian and Alaska Native B03002 | 0.1% | 0.2% | 0.3% |
Economy now FRED unemployment 5.1% in Sep 2026 (5.5% a year earlier); per capita personal income $90,957 in 2025, up 30% in five years (+4.3% after inflation); the state; Source: FRED, Federal Reserve Bank of St. Louis.
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Concord, CA.
Comments